Education
About Us
Working with TipRanks
Follow Us
ExpreS2ion Biotech Holding AB (DE:5JD0)
:5JD0
Total Valuation
ExpreS2ion Biotech Holding AB has a market cap or net worth of €5.50M. The enterprise value is -€30.14M.
Market Cap€5.50M
Enterprise Value-€30.14M
Share Statistics
ExpreS2ion Biotech Holding AB has 2,658,346 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,658,346
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ExpreS2ion Biotech Holding AB’s return on equity (ROE) is -0.57 and return on invested capital (ROIC) is -83.00%.
Return on Equity (ROE)-0.57
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-83.00%
Return on Capital Employed (ROCE)-1.02
Revenue Per Employee150.65K
Profits Per Employee-3.38M
Employee Count20
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ExpreS2ion Biotech Holding AB is -0.96. ExpreS2ion Biotech Holding AB’s PEG ratio is -0.08.
PE Ratio-0.96
PS Ratio0.00
PB Ratio0.66
Price to Fair Value0.54
Price to FCF-1.47
Price to Operating Cash Flow-1.26
PEG Ratio-0.08
Income Statement
In the last 12 months, ExpreS2ion Biotech Holding AB had revenue of 3.01M and earned -36.41M in profits. Earnings per share was -21.54.
Revenue3.01M
Gross Profit-2.67M
Operating Income-67.69M
Pretax Income-44.56M
Net Income-36.41M
EBITDA-64.34M
Earnings Per Share (EPS)-21.54
Cash Flow
In the last 12 months, operating cash flow was -33.93M and capital expenditures -870.00K, giving a free cash flow of -34.80M billion.
Operating Cash Flow-33.93M
Free Cash Flow-34.80M
Free Cash Flow per Share-13.09
Dividends & Yields
ExpreS2ion Biotech Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.01
52-Week Price Change-39.01%
50-Day Moving Average1.80
200-Day Moving Average2.09
Relative Strength Index (RSI)55.13
Average Volume (3m)0.00
Important Dates
ExpreS2ion Biotech Holding AB upcoming earnings date is Aug 21, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 21, 2025
Ex-Dividend Date―
Financial Position
ExpreS2ion Biotech Holding AB as a current ratio of 2.48, with Debt / Equity ratio of 0.56%
Current Ratio2.48
Quick Ratio2.48
Debt to Market Cap0.01
Net Debt to EBITDA1.26
Interest Coverage Ratio-93.12
Taxes
In the past 12 months, ExpreS2ion Biotech Holding AB has paid -8.15M in taxes.
Income Tax-8.15M
Effective Tax Rate0.18
Enterprise Valuation
ExpreS2ion Biotech Holding AB EV to EBITDA ratio is 0.72, with an EV/FCF ratio of 1.33.
EV to Sales-15.38
EV to EBITDA0.72
EV to Free Cash Flow1.33
EV to Operating Cash Flow1.37
Balance Sheet
ExpreS2ion Biotech Holding AB has €81.54M in cash and marketable securities with kr360.00K in debt, giving a net cash position of -€81.18M billion.
Cash & Marketable Securities€81.54M
Total Debtkr360.00K
Net Cash-€81.18M
Net Cash Per Share-€30.54
Tangible Book Value Per Share€38.10
Margins
Gross margin is -488.65%, with operating margin of -2246.76%, and net profit margin of -1208.60%.
Gross Margin-488.65%
Operating Margin-2246.76%
Pretax Margin-1479.02%
Net Profit Margin-1208.60%
EBITDA Margin-2135.41%
EBIT Margin-1454.90%
Analyst Forecast
The average price target for ExpreS2ion Biotech Holding AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―